Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 07 Jul 2026
Third molar removal may improve oral health markers, but its benefits must be weighed against surgical risks, postoperative morbidity, and cost.
Read Full NewsStopping aspirin early in dual antiplatelet therapy is tied to a lower risk for bleeding with no increase in ischemic risks after coronary stenting, a new meta-analysis finds.
The World Health Organization on Thursday declared the hantavirus outbreak linked to a cruise ship over after the last identified contact of an exposed person completed...
New South Wales became Australia's third state to confirm a case of H5N1 bird flu after authorities said a migratory seabird found near a coastal town returned a positive...
The $500 million seed fund will support universal antiviral platforms and air cleaning technologies.
New study finds nearly 10% of internal medicine residents report a disability; the American Medical Association updates maternity care billing codes; and Texas joins autism trial network.
A UK trial finds that low-dose atropine modestly slows childhood myopia progression and axial eye growth over 2 years without increasing adverse events.
A phase 3 trial compares first-line fixed-duration venetoclax-obinutuzumab to fludarabine, cyclophosphamide, and rituximab/bendamustine-rituximab in patients with CLL.
1.
Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.
2.
FDA Approves Novel Targeted Therapy for Rare Blood Cancer
3.
Exercise can counter detrimental effects of cancer treatment, review suggests
4.
The biology of cancer as well as potential treatment options are examined by experts.
5.
The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.
1.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
2.
Transformative Approaches in Hematology for Healthcare Excellence
3.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
4.
The Predictive Power of Targeted Radionuclide Therapy in Advanced Breast Cancer
5.
The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Efficient Management of First line ALK-rearranged NSCLC
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge